Medication info

Sambika Tablet 10/40 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Amlodipine Besylate›13.888mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tablet
Manufacturer / importer
Samsung Pharm Co., Ltd.
Appearance
Brownish-red round film-coated tablets
Packaging
30 tablets (10 tablets/PTP X 3)
Approval status
Expired

MFDS item code 201902835 · Approved 2019.05.02

This product's status changed to Expired on 2024.05.02. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal insufficiency (creatine clearance 20-60mL/min) is 20 mg once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal insufficiency. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be monitored closely. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not receive this medicine, under Precautions for Use.) ∘Elderly patients: Generally, start treatment at a low dose. When adjusting the dose, take the patient's renal or cardiac function and comorbidities into consideration. In elderly patients, blood pressure should be monitored closely and more frequently.
Child dose
∘Pediatrics: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Samsung Pharm Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used in patients with essential hypertension who find it difficult to control blood pressure with monotherapy of amlodipine or olmesartan medoxomil, helping to effectively lower and manage blood pressure. Such treatment contributes to the prevention of cardiovascular diseases and overall health improvement.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal insufficiency (creatine clearance 20-60mL/min) is 20 mg once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal insufficiency. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be monitored closely. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not receive this medicine, under Precautions for Use.) ∘Elderly patients: Generally, start treatment at a low dose. When adjusting the dose, take the patient's renal or cardiac function and comorbidities into consideration. In elderly patients, blood pressure should be monitored closely and more frequently.

Child dose

∘Pediatrics: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm or even death to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it must be stopped immediately if pregnancy is confirmed. Patients with hypersensitivity to any component of this medication, or those who are pregnant or breastfeeding, patients with severe liver dysfunction, severe aortic stenosis, biliary obstruction, renal dialysis, in shock, certain diabetic patients, and those with kidney dysfunction should not take this medication. Patients who are depleted of fluids or salt, those with vasodilation, severe coronary artery disease, congestive heart failure, impaired kidney function, liver dysfunction, etc. should use this medication with increased caution, and their condition must be closely monitored. This medication may cause various side effects, such as dizziness, headache, hypotension, edema, dyspepsia, rash, myalgia, erectile dysfunction, so if any abnormal symptoms occur, consult a doctor immediately. It is advised not to use this medication during pregnancy, especially after the second trimester due to a high risk of fetal harm. Breastfeeding women are recommended to stop breastfeeding or discontinue the medication, as it can be transmitted through breast milk to the baby and affect them. It is not recommended for children under 18 years of age as the safety and efficacy have not been established. For the elderly, it should be initiated at a low dose, considering the possibility of impaired kidney and liver function, and it should be administered cautiously. In case of overdose, severe hypotension, vascular dilation, and tachycardia may occur, so it is essential to adhere strictly to the prescribed dosage and visit a medical facility immediately if overdosing occurs. This medication should be stored away from moisture, heat, and direct sunlight, and it should be kept out of reach of children. Transferring to other containers should be avoided. This medication may interact with other antihypertensive agents or specific drugs, so if you are taking other medications, be sure to inform your doctor or pharmacist. Suddenly stopping beta-blockers can be dangerous, so if discontinuing beta-blocker treatment, the dosage should be reduced gradually. If severe diarrhea occurs similar to chronic malabsorption syndrome, this medication should be discontinued and a healthcare provider consulted. Patients with cardiovascular diseases should be cautious not to have excessively low blood pressure, and regular check-ups and monitoring may be necessary.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • hypesthesia
  • syncope
Show 81 more
  • vertigo
  • palpitations
  • tachycardia
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • low back pain
  • frequent urination
  • erectile dysfunction
  • peripheral edema
  • edema
  • pitting edema
  • fatigue
  • asthenia
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decrease in hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • worsening of cerebral infarction
  • gum bleeding
  • postural dizziness
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • herpes zoster
  • diplopia
  • insomnia
  • asthenia
  • angioedema
  • chronic malabsorption syndrome
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • flushing
  • fatigue
  • edema
  • palpitations
  • vertigo
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • hypotension
  • tachycardia
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a sealed container. The recommended storage temperature is room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Brownish-red round film-coated tablets

Package unit

30 tablets (10 tablets/PTP X 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.